Besifovir (INN) is an investigational medication to treat hepatitis B virus (HBV) infection. It is a novel and potent acyclic nucleotide phosphonate with a similar chemical structure to adefovir and tenofovir.[2]
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C10H14N5O4P |
Molar mass | 299.227 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) |
References
edit- ^ WHO International Working Group for Drug Statistics Methodology (August 27, 2008). "ATC/DDD Classification (FINAL): New ATC 5th level codes". WHO Collaborating Centre for Drug Statistics Methodology. Archived from the original on 2008-05-06. Retrieved 2008-09-05.
- ^ Lin CL, Yang HC, Kao JH (4 January 2016). "Hepatitis B virus: new therapeutic perspectives". Liver Int. 36 (Supplement S1): 85–92. doi:10.1111/liv.13003. PMID 26725903.